Millennium Pharmaceuticals to Acquire COR Therapeutics in $2.0 Billion Deal

Millennium Pharmaceuticals to Acquire COR Therapeutics in $2.0 Billion Deal

Firm News

On December 6, 2001, Millennium Pharmaceuticals, Inc. (Nasdaq: MLNM) announced that it had signed a definitive agreement to acquire COR Therapeutics, Inc. (Nasdaq: CORR) in a stock-for-stock exchange valued at $2.0 billion.

Millennium was advised by the following Hale and Dorr lawyers:

  • on corporate and securities matters, partners David Redlick, Jeff Stein and Jonathan Wolfman, junior partner Ken Lepage and associate Kris Spreen;
  • on intellectual property and licensing matters, partner Steven Singer, junior partner Michael Twomey and associates Jan Siok and Soojin Chung;
  • on tax matters, partner Rob Burke and associate Erika Buell;
  • on real estate matters, partner Keith Barnett;
  • on environmental matters, partner Rob Kirsch and associate Pat van der Voorn;
  • on employee benefits matters, partner Bill Schmidt; and
  • on immigration matters, partner Carolyn Fuchs.

Notice

Unless you are an existing client, before communicating with WilmerHale by e-mail (or otherwise), please read the Disclaimer referenced by this link.(The Disclaimer is also accessible from the opening of this website). As noted therein, until you have received from us a written statement that we represent you in a particular manner (an "engagement letter") you should not send to us any confidential information about any such matter. After we have undertaken representation of you concerning a matter, you will be our client, and we may thereafter exchange confidential information freely.

Thank you for your interest in WilmerHale.